The practical nurse (PN) is obtaining information from a female client who is starting a new prescription for conjugated estrogens 0.625 mg PO daily. Prior to the client taking the first dose of the medication, which information should the PN obtain?

Choice A reason: Immune status is critical before administering the influenza vaccine, as immunocompromised individuals may have reduced vaccine efficacy or increased risk of adverse reactions. Conditions like HIV or chemotherapy weaken immune responses, requiring tailored vaccination strategies. Assessing immune status ensures the vaccine is safe and effective, guiding clinical decisions.

Choice B reason: While age influences vaccine type (e.g., high-dose for older adults), it is less critical than immune status for safety. Age is typically already known from records and does not directly affect immediate vaccine administration decisions. This choice is less relevant compared to immune status evaluation.

Choice C reason: Food allergies are generally irrelevant to influenza vaccines, which are not derived from food allergens. However, egg allergies may be considered for certain vaccines due to manufacturing processes, but this is distinct from food allergies broadly. This choice is incorrect as it lacks direct relevance.

Choice D reason: Gender does not impact influenza vaccine administration. Vaccine efficacy and safety are not significantly influenced by gender-specific physiological differences. This choice is incorrect, as it does not provide critical information needed to ensure the vaccine’s safety or effectiveness for the client.

Choice A reason: Montelukast is a leukotriene receptor antagonist that inhibits leukotrienes, mediators of inflammation in allergic responses. By blocking these, it reduces airway inflammation, bronchoconstriction, and mucus production, preventing asthma or allergic rhinitis symptoms. This prophylactic action targets the immune response to allergens, stabilizing respiratory function before symptoms escalate.

Choice B reason: Montelukast does not increase mucus production. Instead, it reduces mucus by inhibiting leukotriene-driven inflammation in the airways. Increased mucus is a symptom of uncontrolled asthma or allergies, which montelukast aims to prevent. This choice is incorrect as it contradicts the drug’s mechanism of reducing inflammatory responses in the lungs.

Choice C reason: Montelukast does not contract respiratory smooth muscles. It prevents bronchoconstriction by blocking leukotrienes, which cause smooth muscle contraction in asthma. By inhibiting this pathway, it promotes airway relaxation, not contraction. This choice is incorrect, as it misrepresents the drug’s role in maintaining open airways.

Choice D reason: Montelukast does not repair damaged lung tissue. Its primary role is to prevent inflammation and bronchoconstriction caused by allergens. Lung tissue repair involves other physiological processes, not influenced by montelukast. This choice is incorrect, as it falsely attributes tissue regeneration to a drug focused on immune modulation.